Categorized | Feature, Prostate Health

Label Switch in Pfizer Drugs

There is a possible label switch in two of Pfizer’s drugs – an antidepressant and a drug used to shrink the prostate.  This prompted Pfizer to do a subsidiary recall on both drugs.

The affected drugs are both in generic formulation -  Citalopram is an antidepressant and Finasteride is used to treat benign prostatic hyperplasia (BPH).

It is said that only one lot was affected.  Bottles labeled as Citalopram Lot # F10510058-A may contain Finasteride.  The lot number involves Citalopram in 100-count  bottles of 10-mg tables and Finasteride In 90-count bottles of 5-mg tablets.

Greenstone LLC, the Pfizer unit selling the products stressed that patients taking the wrong medications may be at risk for serious side effects.  Patients who discontinue Citalopram abruptly may experience withdrawal symptoms and/or worsening depression. Women who are, or may become pregnant, should not take or handle Finasteride due to possible risk of abnormalities to the external genitalia of a developing male fetus.

Patients should check their bottles of either drug with this lot number on the label should return the products to the pharmacy.

The recall stemmed from the possibility that incorrect labels have been placed on the bottles by a third party manufacturer.

Comments are closed.